Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

16.7%

1 terminated/withdrawn out of 6 trials

Success Rate

80.0%

-6.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 1
6(100.0%)
6Total
Phase 1(6)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT06182579Phase 1Terminated

Phase I Study of RiMO-401 With Radiation in Advanced Tumors

Role: lead

NCT05838729Phase 1Recruiting

Study of RiMO-301 and Radiotherapy With PD-1 Inhibitor for the Treatment of Head-Neck Cancer

Role: lead

NCT03444714Phase 1Completed

Phase I Study of RiMO-301 With Radiation in Advanced Tumors

Role: lead

NCT04808453Phase 1Completed

Phase I Study of CPI-300 in Patients With Advanced Tumors

Role: lead

NCT03781362Phase 1Completed

Study of CPI-100 in Patients With Advanced Tumors

Role: lead

NCT03953742Phase 1Completed

Study of CPI-200 in Patients With Advanced Tumors

Role: lead

All 6 trials loaded